Revvity (RVTY) said Thursday it has signed a new agreement with Genomics England to further collaborate on the Generation Study, a national initiative to screen up to 100,000 newborns for more than 200 rare genetic disorders.
Under the new contract, Revvity said it will also provide DNA sequencing services to help screen newborns for rare genetic conditions, adding to its previous DNA extraction services.
The firm said it will now be able to provide an end-to-end solution with a localized lab facility to advance the screening process.
Price: 107.11, Change: -2.81, Percent Change: -2.56
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。